Biofilm formation by clinical Clostridium perfringens isolates and its suppression by thymol
Poultry Science · 2026
DOI: 10.1016/j.psj.2026.106409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Poultry Science, 2026. Verfasst von Shailes Bhattrai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Animal Biosciences and Biotechnology Laboratory, Beltsville Agricultural Research Center, Agricultural Research Service-US Department of Agriculture,…. Hauptthemen laut MEDLINE: Biofilms, Clostridium perfringens, Thymol, Poultry Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Armenian Relief Society, USDA Agricultural Research Service.
Abstract (Originalsprache)
Necrotic enteritis (NE) caused by Clostridium perfringens imposes major health and economic losses in broiler production, especially with coccidiosis co-infection. Beyond toxin secretion, C. perfringens forms biofilms that enhance persistence and reduce treatment efficacy. Thymol, a phenol from thyme, has broad antimicrobial and antibiofilm activities, but its effects on C. perfringens biofilms are not well defined. We profiled 23 clinical isolates, genotyped them (all cpa ⁺, most cpβ2 ⁺; eight netB ⁺; tpeL detected only in LLY_TpeL17), quantified biofilm biomass by 0.1% crystal violet staining (OD 570 ) with and without 1% glucose, and tested thymol (6.25-1600 µg/mL) in a microplate model for effects on planktonic growth (OD 590 ) and biofilm formation. Biofilm capacity varied widely, and glucose increased baseline biomass. Thymol inhibited planktonic growth and biofilm biomass in a dose-dependent manner, with the minimum inhibitory concentration (MIC) values of approximately 100 µg/mL in glucose-deprived medium and 200 µg/mL in 1% glucose-supplemented medium, where biofilm formation was significantly reduced at sub-MIC concentrations (25-50 µg/mL) under both conditions. In mature 72-h biofilms from high-biofilm producers, a 3-h thymol exposure reduced metabolic activity (resazurin RFU) and biomass, with strong effects at 50-100 µg/mL and near-baseline signals at ≥200 µg/mL. These findings reveal substantial isolate-to-isolate variability and support thymol as a promising natural antimicrobial and antibiofilm agent for NE control in poultry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Animal Biosciences and Biotechnology Laboratory, Beltsville Agricultural Research Center, Agricultural Research Service-US Department of Agriculture, Beltsville, MD 20705, USA; The Oak Ridge Institute for Science and Ed…
- Animal Biosciences and Biotechnology Laboratory, Beltsville Agricultural Research Center, Agricultural Research Service-US Department of Agriculture, Beltsville, MD 20705, USA.
- Animal Parasitic Diseases Laboratory, Beltsville Agricultural Research Center, Agricultural Research Service-US Department of Agriculture, Beltsville, MD 20705, USA.
- Animal Biosciences and Biotechnology Laboratory, Beltsville Agricultural Research Center, Agricultural Research Service-US Department of Agriculture, Beltsville, MD 20705, USA. Electronic address: charles.li@usda.gov.
Förderung
- Armenian Relief Society
- USDA Agricultural Research Service
Zitieren
APA
Bhattrai, S., Sun, Z., Jenkins, M., Parker, C., Lillehoj, H., & Li, C. (2026). Biofilm formation by clinical Clostridium perfringens isolates and its suppression by thymol. Poultry Science. https://doi.org/10.1016/j.psj.2026.106409
Vancouver
Bhattrai S, Sun Z, Jenkins M, Parker C, Lillehoj H, Li C. Biofilm formation by clinical Clostridium perfringens isolates and its suppression by thymol. Poultry Science. 2026. doi:10.1016/j.psj.2026.106409
BibTeX
@article{Bhattrai2026,
author = {Bhattrai, Shailes and Sun, Zhifeng and Jenkins, Mark and Parker, Carolyn and Lillehoj, Hyun and Li, Charles},
title = {Biofilm formation by clinical Clostridium perfringens isolates and its suppression by thymol},
journal = {Poultry Science},
year = {2026},
doi = {10.1016/j.psj.2026.106409}
}
EUVIMED